106 related articles for article (PubMed ID: 33704713)
1. Evaluating Melanoma Viability and Proliferation in 3D Microenvironments.
Siruvallur Murali V; Cobanoglu MC; Welf ES
Methods Mol Biol; 2021; 2265():155-171. PubMed ID: 33704713
[TBL] [Abstract][Full Text] [Related]
2. An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments.
Murali VS; Chang BJ; Fiolka R; Danuser G; Cobanoglu MC; Welf ES
BMC Cancer; 2019 May; 19(1):502. PubMed ID: 31138163
[TBL] [Abstract][Full Text] [Related]
3. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
4. Novel 3D Liquid Cell Culture Method for Anchorage-independent Cell Growth, Cell Imaging and Automated Drug Screening.
Abe-Fukasawa N; Otsuka K; Aihara A; Itasaki N; Nishino T
Sci Rep; 2018 Feb; 8(1):3627. PubMed ID: 29483620
[TBL] [Abstract][Full Text] [Related]
5. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
7. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
8. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
9. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
Brighton HE; Angus SP; Bo T; Roques J; Tagliatela AC; Darr DB; Karagoz K; Sciaky N; Gatza ML; Sharpless NE; Johnson GL; Bear JE
Cancer Res; 2018 Jan; 78(2):542-557. PubMed ID: 29180473
[TBL] [Abstract][Full Text] [Related]
10. Novel three-dimensional cultures provide insights into thyroid cancer behavior.
Lee MA; Bergdorf KN; Phifer CJ; Jones CY; Byon SY; Sawyer LM; Bauer JA; Weiss VL
Endocr Relat Cancer; 2020 Feb; 27(2):111-121. PubMed ID: 31804972
[TBL] [Abstract][Full Text] [Related]
11. Clinical protein science in translational medicine targeting malignant melanoma.
Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G
Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics.
Thakuri PS; Gupta M; Plaster M; Tavana H
Assay Drug Dev Technol; 2019 Apr; 17(3):140-149. PubMed ID: 30958703
[TBL] [Abstract][Full Text] [Related]
13. Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Rice W; Qiu J; Chan LL
Cytometry A; 2017 Sep; 91(9):883-892. PubMed ID: 28618188
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Micel LN; Tentler JJ; Tan AC; Selby HM; Brunkow KL; Robertson KM; Davis SL; Klauck PJ; Pitts TM; Gangolli E; Fabrey R; O'Connell SM; Vincent PW; Eckhardt SG
Mol Cancer Ther; 2015 Feb; 14(2):317-25. PubMed ID: 25376610
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.
Bernhardt M; Orouji E; Larribere L; Gebhardt C; Utikal J
Clin Cancer Res; 2014 May; 20(9):2498-9. PubMed ID: 24789037
[No Abstract] [Full Text] [Related]
16. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
[No Abstract] [Full Text] [Related]
17. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
18. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
[TBL] [Abstract][Full Text] [Related]
19. Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Lee Y; Park D
Anticancer Res; 2021 Mar; 41(3):1387-1399. PubMed ID: 33788730
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
Mizukami Y; Kanemaru H; Nakamura K; Hashigo S; Kajihara I; Miyashita A; Aoi J; Fukushima S; Honda Y; Ihn H
J Dermatol; 2020 Apr; 47(4):e126-e127. PubMed ID: 31872454
[No Abstract] [Full Text] [Related]
[Next] [New Search]